Glaucoma Treatment Market By Glaucoma Type (Open-Angle Glaucoma, Angle-Closure Glaucoma, Normal-Tension Glaucoma, and Others); By Medication (Alpha Adrenergic Agonists, Beta Blockers, Carbonic Anhydrase Inhibitors, Miotics, Prostaglandin Analogs, Combination Medication, and Others); By Route of Administration (Oral and Topical); By Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies); By Region (North America (U.S., Canada, Mexico, & Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden & Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), & Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore & Rest of Southeast Asia), & Rest of Asia Pacific), Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, & Rest of Middle East & Africa) Latin America (Brazil, Argentina, & Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
In the global glaucoma treatment market, the major driver contributing to the market growth is rising initiatives to increase awareness about glaucoma. Glaucoma is a painless disorder of the eye where patient does not notice any kind of symptoms until noticeable vision loss. Moreover, the number of patients suffering from glaucoma is increasing day by day. Growing awareness campaigns about glaucoma are being carried out by government and pharmaceutical companies that are boosting the growth of the global glaucoma treatment market. In March 2021, researchers from City, University London, with support from Allergan Pharmaceuticals and Glaucoma UK, released the latest edition of an app to help people newly diagnosed with glaucoma. Increasing production of alpha-adrenergic agonists, beta-blockers, carbonic anhydrase inhibitors, and prostaglandin analogs is also contributing towards the growth of global glaucoma treatment market. Other factors contributing to the market growth include introduction of more efficient eye drops, increasing investment in glaucoma treatment by pharmaceutical companies as well as biotechnological companies, and increasing production of combination medication drugs. Technological advancement in the field indicate substantial growth prospects for global glaucoma treatment market over the forecast period. In September 2021, the scientists at Nanyang Technological University and clinicians from the Tan Tock Seng Hospital in Singapore joined hands to develop an artificial intelligence (AI)-based method of screening patients for glaucoma. Now scientists are working on bringing algorithms to a mobile phone app that can be used as a screening tool in the field.
Stringent approval process is a big restraint in the growth of global glaucoma treatment market. Due to complications involved in the post-surgery treatment, governments in many countries have imposed stringent measures regarding approval process in order to ensure that glaucoma treatment methods have no or minimal unfavorable side-effects.
Glaucoma is defined as a group of eye diseases that damage to the optic nerve, causing vision loss. The most common type of glaucoma are open-angle glaucoma and closed-angle glaucoma, and normal-tension glaucoma. As glaucoma is second leading cause of blindness across the world, doctors use a tonometer to measure intraocular pressure (IOP) during routine eye checkups. According to 2019 statistics by World Health Organization (WHO), more than 60 million people all over the world were suffering from glaucoma.
Due to impact of China-originated coronavirus, many glaucoma cases all over the world are worsening as many people who were previously diagnosed could not receive timely treatment as treatment for medical problems that were not life-threatening was postponed as whole medical sector is struggling to contain COVID-19. Hence, many people lost their visual acuity. This was an irretrievable loss for every victim. Due to fear of COVID infection, many people could not go to doctors for specialist's consultation. Hence, now routine screenings and pressure checks for glaucoma patients were not possible. Although tube shunts required fewer visits from doctors to patients, closures caused by lockdowns meant to prevent the spread of COVID infections, many doctors missed some postoperative visits with tube shunt patients. Hence, concerns about hypotony arose.
Laser therapy for glaucoma treatment is anticipated to contribute towards the growth of glaucoma treatment market. In some countries, the use of laser therapy is allowed for glaucoma treatment. Different types of laser surgeries that are used for treating glaucoma include argon laser trabeculoplasty (ALT), Laser Cyclophotocoagulation, laser peripheral iridotomy (LPI), selective laser trabeculoplasty (SLT), and many others. In April 2021, a study concluded that SLT was effective in lowering intraocular pressure with satisfactory success rates. A single SLT was sufficient to achieve desired results. As SLT is a therapy not depending on patient adherence, many doctors preferred it as adherence was low among glaucoma patients.
In terms of revenue, glaucoma treatment market was valued at US$ 2930.68 Mn in 2020 growing at a CAGR of 3.8% over the forecast period (2021 – 2029). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Glaucoma Treatment Market Revenue & Forecast, (US$ Million), 2015 – 2029
Glaucoma Type Outlook:
As per the glaucoma type, the global glaucoma treatment market is segmented into open-angle glaucoma, angle-closure glaucoma, normal-tension glaucoma, and others. The open-angle glaucoma segment accounted for the largest market share in the global glaucoma treatment market in 2020 and during the forecast period (2021 – 2029), this segment is estimated to continue its success and stand as the fastest growing market segment. This is the most common type of glaucoma and is also known as wide-angle glaucoma. Substantial investments directed towards the introduction of adequate treatment modalities for the concern is aiding the segment’s growth in the global market. For instance, in November 2017, Bausch & Lomb Inc., launched the VYZULTA solution. This solution assists in the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension.
Medication Outlook:
In the context of medication, the global glaucoma treatment market has been primarily segmented into alpha adrenergic agonists, beta blockers, carbonic anhydrase inhibitors, miotics, prostaglandin analogs, combination medication, and others. The alpha adrenergic agonists segment accounted for the largest market share in 2020. This medication not only reduces aqueous humor production but also increases its outflow. The most popular alpha adrenergic agonists are Iopidine (containing Apraclonidine), Alphagan (containing Brimonidine), Propine (containing Dipivefrin), Gluacon (containing Epinepherine), and Epifrin (containing Epinepherine). Eye drops containing beta-blockers and alpha-adrenergic agonists are commonly used to treat glaucoma. Strategic initiatives undertaken by the market participants are contributing towards the segment’s growth. In April 2021, for example, Alcon acquired commercialization rights to Ophthalmic Eye Drop Simbrinza in USA. Simbrinza is a fixed combination of a carbonic anhydrase inhibitor and an alpha-2 adrenergic receptor agonist. Simbrinza reduces elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. However, combination medication segment is expected to achieve tremendous growth in global glaucoma treatment market during the forecast period.
Route of Administration Outlook:
On the basis of route of administration segment of global glaucoma treatment market, the market has been segmented into oral administration and topical administration. Topical administration accounted for the largest market share in glaucoma treatment market in 2020 and during the forecast period (2021 – 2029), this segment is estimated to witness highest growth rate. The treatment of any type of glaucoma starts with topical administration of eye drops. The increasing launch of new products is also expected to replace the existing formulations to accelerate the market growth. For instance, in October 2019, Bausch + Lomb launched the PreserVision AREDS 2 Formula mini-gel eye vitamins in the USA. These vitamins are useful for the treatment of moderate to advanced Age-related macular degeneration (AMD).
Distribution Channels Outlook:
Considering the distribution channels, the global glaucoma treatment market has been segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest market segment in 2020. It has been among the traditional sources of buying medicines and vaccines. However, ease of accessibility and convenience of online purchase is driving the growth of online pharmacies, which is anticipated to witness highest growth rate over the forecast period.
Region Outlook:
North America accounted for a significant share in the glaucoma treatment market in 2020. However, during the forecast period, the Asia Pacific region is expected to witness highest growth rate due to increasing geriatric population in China and Japan. According to the statistics from World Bank, 28% of Japan's population is over 65 years old. In 2020, Japan had 2,886,961 diagnosed cases for Glaucoma. During this period, around 11.47% of the China population was over 65 years. Governments of many Asian countries such as India, China, Japan, South Korea, and Singapore are increasing focus on enhancing healthcare facilities. Rising awareness among the population of Asian countries is also contributing to the market growth in the Asia Pacific region. According to WHO, around 6.8% of GDP, combining the GDP of all countries of Asia Pacific countries was the healthcare expenditure in this region. Other factors contributing the market growth include increasing technological advancement and increasing development of medical infrastructure in Asian countries such as Japan, Singapore, & South Korea. Governments in Asian countries are also encouraging more research for drugs as well as technology that can ease medical treatments. In October 2020, Santen and Aerie concluded an exclusive license agreement for the production and sales of Rocklatan and Rhopressa in Japan and several other Asian countries. The two partners intend to make further joint contribute to the treatment of glaucoma patients through these products. Santen has a huge sales platform and Aerie has a huge network ophthalmologists in Japan and other Asian countries.
Competitive Landscape Outlook:
The report provides both, qualitative as well as quantitative research of global glaucoma treatment market. It also provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as affiliations, collaborations, mergers & acquisitions (M&A), and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the glaucoma treatment market are Aerie Pharmaceuticals, Inc., ALLERGAN, Bausch & Lomb Incorporated, EyeD Pharma s.a., Merck & Co., Inc., Pfizer, Santen Pharmaceutical Co. Ltd., Senju Pharmaceutical Co. Ltd., and Sunways India Pvt Ltd., amongst other market participants.
Global Glaucoma Treatment Market:
By Glaucoma Type
- Open-Angle Glaucoma
- Angle-Closure Glaucoma
- Normal-Tension Glaucoma
- Others
By Medication
- Alpha Adrenergic Agonists Highest Share
- Beta Blockers
- Carbonic Anhydrase Inhibitors
- Miotics
- Prostaglandin Analogs
- Combination Medication Fastest Growing
- Others
By Route of Administration
- Oral
- Topical
By Distribution Channels
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic Years: 2015 - 2019
1.2.2. Base Year: 2020
1.2.3. Forecast Years: 2021 – 2029
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market
Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Glaucoma Treatment Market
6. Market Synopsis:
Glaucoma Treatment Market
7. Glaucoma Treatment Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Glaucoma Treatment Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Glaucoma Treatment Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on Glaucoma Treatment Market
8. Global Glaucoma Treatment Market Analysis and Forecasts, 2021
– 2029
8.1. Overview
8.1.1. Global Glaucoma Treatment Market Revenue (US$ Mn)
8.2. Global
Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By Glaucoma Type
8.2.1. Open-Angle Glaucoma
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 - 2020
8.2.1.3. Market Forecast, 2021 - 2029
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market
Estimation, 2015 - 2020
8.2.1.5.1.2. Market
Forecast, 2021 - 2029
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 - 2020
8.2.1.5.2.2. Market
Forecast, 2021 - 2029
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market
Estimation, 2015 - 2020
8.2.1.5.3.2. Market
Forecast, 2021 - 2029
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 - 2020
8.2.1.5.4.2. Market
Forecast, 2021 - 2029
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market
Estimation, 2015 - 2020
8.2.1.5.5.2. Market
Forecast, 2021 - 2029
8.2.2. Angle-Closure Glaucoma
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2020
8.2.2.3. Market Forecast, 2021 - 2029
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market
Estimation, 2015 - 2020
8.2.2.5.1.2. Market
Forecast, 2021 - 2029
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 - 2020
8.2.2.5.2.2. Market
Forecast, 2021 - 2029
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market
Estimation, 2015 - 2020
8.2.2.5.3.2. Market
Forecast, 2021 - 2029
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 - 2020
8.2.2.5.4.2. Market
Forecast, 2021 - 2029
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market
Estimation, 2015 - 2020
8.2.2.5.5.2. Market
Forecast, 2021 - 2029
8.2.3. Normal-Tension Glaucoma
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 - 2020
8.2.3.3. Market Forecast, 2021 - 2029
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market
Estimation, 2015 - 2020
8.2.3.5.1.2. Market
Forecast, 2021 - 2029
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 - 2020
8.2.3.5.2.2. Market
Forecast, 2021 - 2029
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market
Estimation, 2015 - 2020
8.2.3.5.3.2. Market
Forecast, 2021 - 2029
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 - 2020
8.2.3.5.4.2. Market
Forecast, 2021 - 2029
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market
Estimation, 2015 - 2020
8.2.3.5.5.2. Market
Forecast, 2021 - 2029
8.2.4. Others
8.2.4.1. Definition
8.2.4.2. Market Estimation and Penetration, 2015 - 2020
8.2.4.3. Market Forecast, 2021 - 2029
8.2.4.4. Compound Annual Growth Rate (CAGR)
8.2.4.5. Regional Bifurcation
8.2.4.5.1. North America
8.2.4.5.1.1. Market
Estimation, 2015 - 2020
8.2.4.5.1.2. Market
Forecast, 2021 - 2029
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2015 - 2020
8.2.4.5.2.2. Market
Forecast, 2021 - 2029
8.2.4.5.3. Asia Pacific
8.2.4.5.3.1. Market
Estimation, 2015 - 2020
8.2.4.5.3.2. Market
Forecast, 2021 - 2029
8.2.4.5.4. Middle East and Africa
8.2.4.5.4.1. Market
Estimation, 2015 - 2020
8.2.4.5.4.2. Market
Forecast, 2021 - 2029
8.2.4.5.5. Latin America
8.2.4.5.5.1. Market
Estimation, 2015 - 2020
8.2.4.5.5.2. Market
Forecast, 2021 - 2029
8.3. Key Segment
for Channeling Investments
8.3.1. By Glaucoma Type
9. Global Glaucoma Treatment Market Analysis and Forecasts, 2021
– 2029
9.1. Overview
9.2. Global
Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By Medication
9.2.1. Alpha Adrenergic Agonists
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 - 2020
9.2.1.3. Market Forecast, 2021 - 2029
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market
Estimation, 2015 - 2020
9.2.1.5.1.2. Market
Forecast, 2021 - 2029
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 - 2020
9.2.1.5.2.2. Market
Forecast, 2021 - 2029
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market
Estimation, 2015 - 2020
9.2.1.5.3.2. Market
Forecast, 2021 - 2029
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 - 2020
9.2.1.5.4.2. Market
Forecast, 2021 - 2029
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market
Estimation, 2015 - 2020
9.2.1.5.5.2. Market
Forecast, 2021 - 2029
9.2.2. Beta Blockers
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2020
9.2.2.3. Market Forecast, 2021 - 2029
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market
Estimation, 2015 - 2020
9.2.2.5.1.2. Market
Forecast, 2021 - 2029
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 - 2020
9.2.2.5.2.2. Market
Forecast, 2021 - 2029
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market
Estimation, 2015 - 2020
9.2.2.5.3.2. Market
Forecast, 2021 - 2029
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 - 2020
9.2.2.5.4.2. Market
Forecast, 2021 - 2029
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market
Estimation, 2015 - 2020
9.2.2.5.5.2. Market
Forecast, 2021 - 2029
9.2.3. Carbonic Anhydrase Inhibitors
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 - 2020
9.2.3.3. Market Forecast, 2021 - 2029
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market
Estimation, 2015 - 2020
9.2.3.5.1.2. Market
Forecast, 2021 - 2029
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 - 2020
9.2.3.5.2.2. Market
Forecast, 2021 - 2029
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market
Estimation, 2015 - 2020
9.2.3.5.3.2. Market
Forecast, 2021 - 2029
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 - 2020
9.2.3.5.4.2. Market
Forecast, 2021 - 2029
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market
Estimation, 2015 - 2020
9.2.3.5.5.2. Market
Forecast, 2021 - 2029
9.2.4. Miotics
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2015 - 2020
9.2.4.3. Market Forecast, 2021 - 2029
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market
Estimation, 2015 - 2020
9.2.4.5.1.2. Market
Forecast, 2021 - 2029
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 - 2020
9.2.4.5.2.2. Market
Forecast, 2021 - 2029
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market
Estimation, 2015 - 2020
9.2.4.5.3.2. Market
Forecast, 2021 - 2029
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 - 2020
9.2.4.5.4.2. Market
Forecast, 2021 - 2029
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market
Estimation, 2015 - 2020
9.2.4.5.5.2. Market
Forecast, 2021 - 2029
9.2.5. Prostaglandin Analogs
9.2.5.1. Definition
9.2.5.2. Market Estimation and Penetration, 2015 - 2020
9.2.5.3. Market Forecast, 2021 - 2029
9.2.5.4. Compound Annual Growth Rate (CAGR)
9.2.5.5. Regional Bifurcation
9.2.5.5.1. North America
9.2.5.5.1.1. Market
Estimation, 2015 - 2020
9.2.5.5.1.2. Market
Forecast, 2021 - 2029
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2015 - 2020
9.2.5.5.2.2. Market
Forecast, 2021 - 2029
9.2.5.5.3. Asia Pacific
9.2.5.5.3.1. Market
Estimation, 2015 - 2020
9.2.5.5.3.2. Market
Forecast, 2021 - 2029
9.2.5.5.4. Middle East and Africa
9.2.5.5.4.1. Market
Estimation, 2015 - 2020
9.2.5.5.4.2. Market
Forecast, 2021 - 2029
9.2.5.5.5. Latin America
9.2.5.5.5.1. Market
Estimation, 2015 - 2020
9.2.5.5.5.2. Market
Forecast, 2021 - 2029
9.2.6. Combination Medication
9.2.6.1. Definition
9.2.6.2. Market Estimation and Penetration, 2015 - 2020
9.2.6.3. Market Forecast, 2021 - 2029
9.2.6.4. Compound Annual Growth Rate (CAGR)
9.2.6.5. Regional Bifurcation
9.2.6.5.1. North America
9.2.6.5.1.1. Market
Estimation, 2015 - 2020
9.2.6.5.1.2. Market
Forecast, 2021 - 2029
9.2.6.5.2. Europe
9.2.6.5.2.1. Market
Estimation, 2015 - 2020
9.2.6.5.2.2. Market
Forecast, 2021 - 2029
9.2.6.5.3. Asia Pacific
9.2.6.5.3.1. Market
Estimation, 2015 - 2020
9.2.6.5.3.2. Market
Forecast, 2021 - 2029
9.2.6.5.4. Middle East and Africa
9.2.6.5.4.1. Market
Estimation, 2015 - 2020
9.2.6.5.4.2. Market
Forecast, 2021 - 2029
9.2.6.5.5. Latin America
9.2.6.5.5.1. Market
Estimation, 2015 - 2020
9.2.6.5.5.2. Market
Forecast, 2021 - 2029
9.2.7. Others
9.2.7.1. Definition
9.2.7.2. Market Estimation and Penetration, 2015 - 2020
9.2.7.3. Market Forecast, 2021 - 2029
9.2.7.4. Compound Annual Growth Rate (CAGR)
9.2.7.5. Regional Bifurcation
9.2.7.5.1. North America
9.2.7.5.1.1. Market
Estimation, 2015 - 2020
9.2.7.5.1.2. Market
Forecast, 2021 - 2029
9.2.7.5.2. Europe
9.2.7.5.2.1. Market
Estimation, 2015 - 2020
9.2.7.5.2.2. Market
Forecast, 2021 - 2029
9.2.7.5.3. Asia Pacific
9.2.7.5.3.1. Market
Estimation, 2015 - 2020
9.2.7.5.3.2. Market
Forecast, 2021 - 2029
9.2.7.5.4. Middle East and Africa
9.2.7.5.4.1. Market
Estimation, 2015 - 2020
9.2.7.5.4.2. Market
Forecast, 2021 - 2029
9.2.7.5.5. Latin America
9.2.7.5.5.1. Market
Estimation, 2015 - 2020
9.2.7.5.5.2. Market
Forecast, 2021 - 2029
9.3. Key
Segment for Channeling Investments
9.3.1. By Medication
10. Global Glaucoma Treatment Market Analysis and Forecasts, 2021
– 2029
10.1. Overview
10.2. Global
Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
10.2.1. Oral
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2020
10.2.1.3. Market Forecast, 2021 - 2029
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2015 - 2020
10.2.1.5.1.2. Market
Forecast, 2021 - 2029
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 - 2020
10.2.1.5.2.2. Market
Forecast, 2021 - 2029
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2015 - 2020
10.2.1.5.3.2. Market
Forecast, 2021 - 2029
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 - 2020
10.2.1.5.4.2. Market
Forecast, 2021 - 2029
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2015 - 2020
10.2.1.5.5.2. Market
Forecast, 2021 - 2029
10.2.2. Topical
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 - 2020
10.2.2.3. Market Forecast, 2021 - 2029
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market
Estimation, 2015 - 2020
10.2.2.5.1.2. Market
Forecast, 2021 - 2029
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 - 2020
10.2.2.5.2.2. Market
Forecast, 2021 - 2029
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market
Estimation, 2015 - 2020
10.2.2.5.3.2. Market
Forecast, 2021 - 2029
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 - 2020
10.2.2.5.4.2. Market
Forecast, 2021 - 2029
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market
Estimation, 2015 - 2020
10.2.2.5.5.2. Market
Forecast, 2021 - 2029
10.3. Key
Segment for Channeling Investments
10.3.1. By Route of Administration
11. Global Glaucoma Treatment Market Analysis and Forecasts, 2021
– 2029
11.1. Overview
11.2. Global
Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
11.2.1. Hospitals Pharmacies
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 - 2020
11.2.1.3. Market Forecast, 2021 - 2029
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market
Estimation, 2015 - 2020
11.2.1.5.1.2. Market
Forecast, 2021 - 2029
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 - 2020
11.2.1.5.2.2. Market
Forecast, 2021 - 2029
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market
Estimation, 2015 - 2020
11.2.1.5.3.2. Market
Forecast, 2021 - 2029
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 - 2020
11.2.1.5.4.2. Market
Forecast, 2021 - 2029
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market
Estimation, 2015 - 2020
11.2.1.5.5.2. Market
Forecast, 2021 - 2029
11.2.2. Retail Pharmacies
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2015 - 2020
11.2.2.3. Market Forecast, 2021 - 2029
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market
Estimation, 2015 - 2020
11.2.2.5.1.2. Market
Forecast, 2021 - 2029
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2015 - 2020
11.2.2.5.2.2. Market
Forecast, 2021 - 2029
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market
Estimation, 2015 - 2020
11.2.2.5.3.2. Market
Forecast, 2021 - 2029
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market
Estimation, 2015 - 2020
11.2.2.5.4.2. Market
Forecast, 2021 - 2029
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market
Estimation, 2015 - 2020
11.2.2.5.5.2. Market
Forecast, 2021 - 2029
11.2.3. Online Pharmacies
11.2.3.1. Definition
11.2.3.2. Market Estimation and Penetration, 2015 - 2020
11.2.3.3. Market Forecast, 2021 - 2029
11.2.3.4. Compound Annual Growth Rate (CAGR)
11.2.3.5. Regional Bifurcation
11.2.3.5.1. North America
11.2.3.5.1.1. Market
Estimation, 2015 - 2020
11.2.3.5.1.2. Market
Forecast, 2021 - 2029
11.2.3.5.2. Europe
11.2.3.5.2.1. Market
Estimation, 2015 - 2020
11.2.3.5.2.2. Market
Forecast, 2021 - 2029
11.2.3.5.3. Asia Pacific
11.2.3.5.3.1. Market
Estimation, 2015 - 2020
11.2.3.5.3.2. Market
Forecast, 2021 - 2029
11.2.3.5.4. Middle East and Africa
11.2.3.5.4.1. Market
Estimation, 2015 - 2020
11.2.3.5.4.2. Market
Forecast, 2021 - 2029
11.2.3.5.5. Latin America
11.2.3.5.5.1. Market
Estimation, 2015 - 2020
11.2.3.5.5.2. Market
Forecast, 2021 - 2029
11.3. Key
Segment for Channeling Investments
11.3.1. By Distribution Channel
12. North America Glaucoma Treatment Market Analysis and
Forecasts, 2021 - 2029
12.1. Overview
12.1.1. North America Glaucoma Treatment Market Revenue (US$ Mn)
12.2. North America
Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By Glaucoma Type
12.2.1. Open-Angle Glaucoma
12.2.2. Angle-Closure Glaucoma
12.2.3. Normal-Tension Glaucoma
12.2.4. Others
12.3. North
America Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By Medication
12.3.1. Alpha Adrenergic Agonists
12.3.2. Beta Blockers
12.3.3. Carbonic Anhydrase Inhibitors
12.3.4. Miotics
12.3.5. Prostaglandin Analogs
12.3.6. Combination Medication
12.3.7. Others
12.4. North
America Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
12.4.1. Oral
12.4.2. Topical
12.5. North
America Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
12.5.1. Hospitals Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. North
America Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1. U.S Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts,
By Glaucoma Type
12.6.1.1.1. Open-Angle Glaucoma
12.6.1.1.2. Angle-Closure Glaucoma
12.6.1.1.3. Normal-Tension Glaucoma
12.6.1.1.4. Others
12.6.1.2. U.S Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts,
By Medication
12.6.1.2.1. Alpha Adrenergic Agonists
12.6.1.2.2. Beta Blockers
12.6.1.2.3. Carbonic Anhydrase Inhibitors
12.6.1.2.4. Miotics
12.6.1.2.5. Prostaglandin Analogs
12.6.1.2.6. Combination Medication
12.6.1.2.7. Others
12.6.1.3. U.S Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
12.6.1.3.1. Oral
12.6.1.3.2. Topical
12.6.1.4. U.S Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
12.6.1.4.1. Hospitals Pharmacies
12.6.1.4.2. Retail Pharmacies
12.6.1.4.3. Online Pharmacies
12.6.2. Canada
12.6.2.1. Canada Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Glaucoma Type
12.6.2.1.1. Open-Angle Glaucoma
12.6.2.1.2. Angle-Closure Glaucoma
12.6.2.1.3. Normal-Tension Glaucoma
12.6.2.1.4. Others
12.6.2.2. Canada Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Medication
12.6.2.2.1. Alpha Adrenergic Agonists
12.6.2.2.2. Beta Blockers
12.6.2.2.3. Carbonic Anhydrase Inhibitors
12.6.2.2.4. Miotics
12.6.2.2.5. Prostaglandin Analogs
12.6.2.2.6. Combination Medication
12.6.2.2.7. Others
12.6.2.3. Canada Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
12.6.2.3.1. Oral
12.6.2.3.2. Topical
12.6.2.4. Canada Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
12.6.2.4.1. Hospitals Pharmacies
12.6.2.4.2. Retail Pharmacies
12.6.2.4.3. Online Pharmacies
12.6.3. Mexico
12.6.3.1. Mexico Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Glaucoma Type
12.6.3.1.1. Open-Angle Glaucoma
12.6.3.1.2. Angle-Closure Glaucoma
12.6.3.1.3. Normal-Tension Glaucoma
12.6.3.1.4. Others
12.6.3.2. Mexico Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Medication
12.6.3.2.1. Alpha Adrenergic Agonists
12.6.3.2.2. Beta Blockers
12.6.3.2.3. Carbonic Anhydrase Inhibitors
12.6.3.2.4. Miotics
12.6.3.2.5. Prostaglandin Analogs
12.6.3.2.6. Combination Medication
12.6.3.2.7. Others
12.6.3.3. Mexico Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
12.6.3.3.1. Oral
12.6.3.3.2. Topical
12.6.3.4. Mexico Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
12.6.3.4.1. Hospitals Pharmacies
12.6.3.4.2. Retail Pharmacies
12.6.3.4.3. Online Pharmacies
12.6.4. Rest of North America
12.6.4.1. Rest of North America Glaucoma Treatment Market Revenue (US$
Mn) and Forecasts, By Glaucoma Type
12.6.4.1.1. Open-Angle Glaucoma
12.6.4.1.2. Angle-Closure Glaucoma
12.6.4.1.3. Normal-Tension Glaucoma
12.6.4.1.4. Others
12.6.4.2. Rest of North America Glaucoma Treatment Market Revenue (US$
Mn) and Forecasts, By Medication
12.6.4.2.1. Alpha Adrenergic Agonists
12.6.4.2.2. Beta Blockers
12.6.4.2.3. Carbonic Anhydrase Inhibitors
12.6.4.2.4. Miotics
12.6.4.2.5. Prostaglandin Analogs
12.6.4.2.6. Combination Medication
12.6.4.2.7. Others
12.6.4.3. Rest of North America Glaucoma Treatment Market Revenue (US$
Mn) and Forecasts, By Route of Administration
12.6.4.3.1. Oral
12.6.4.3.2. Topical
12.6.4.4. Rest of North America Glaucoma Treatment Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
12.6.4.4.1. Hospitals Pharmacies
12.6.4.4.2. Retail Pharmacies
12.6.4.4.3. Online Pharmacies
12.7. Key
Segment for Channeling Investments
12.7.1. By Country
12.7.2. By Glaucoma Type
12.7.3. By Medication
12.7.4. By Route of Administration
12.7.5. By Distribution Channel
13. Europe Glaucoma Treatment Market Analysis and Forecasts, 2021
- 2029
13.1. Overview
13.1.1. Europe Glaucoma Treatment Market Revenue (US$ Mn)
13.2. Europe
Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By Glaucoma Type
13.2.1. Open-Angle Glaucoma
13.2.2. Angle-Closure Glaucoma
13.2.3. Normal-Tension Glaucoma
13.2.4. Others
13.3. Europe
Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By Medication
13.3.1. Alpha Adrenergic Agonists
13.3.2. Beta Blockers
13.3.3. Carbonic Anhydrase Inhibitors
13.3.4. Miotics
13.3.5. Prostaglandin Analogs
13.3.6. Combination Medication
13.3.7. Others
13.4. Europe
Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.4.1. Oral
13.4.2. Topical
13.5. Europe
Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By Distribution
Channel
13.5.1. Hospitals Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Europe
Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1. France Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Glaucoma Type
13.6.1.1.1. Open-Angle Glaucoma
13.6.1.1.2. Angle-Closure Glaucoma
13.6.1.1.3. Normal-Tension Glaucoma
13.6.1.1.4. Others
13.6.1.2. France Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Medication
13.6.1.2.1. Alpha Adrenergic Agonists
13.6.1.2.2. Beta Blockers
13.6.1.2.3. Carbonic Anhydrase Inhibitors
13.6.1.2.4. Miotics
13.6.1.2.5. Prostaglandin Analogs
13.6.1.2.6. Combination Medication
13.6.1.2.7. Others
13.6.1.3. France Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.6.1.3.1. Oral
13.6.1.3.2. Topical
13.6.1.4. France Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.6.1.4.1. Hospitals Pharmacies
13.6.1.4.2. Retail Pharmacies
13.6.1.4.3. Online Pharmacies
13.6.2. The UK
13.6.2.1. The UK Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Glaucoma Type
13.6.2.1.1. Open-Angle Glaucoma
13.6.2.1.2. Angle-Closure Glaucoma
13.6.2.1.3. Normal-Tension Glaucoma
13.6.2.1.4. Others
13.6.2.2. The UK Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Medication
13.6.2.2.1. Alpha Adrenergic Agonists
13.6.2.2.2. Beta Blockers
13.6.2.2.3. Carbonic Anhydrase Inhibitors
13.6.2.2.4. Miotics
13.6.2.2.5. Prostaglandin Analogs
13.6.2.2.6. Combination Medication
13.6.2.2.7. Others
13.6.2.3. The UK Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.6.2.3.1. Oral
13.6.2.3.2. Topical
13.6.2.4. The UK Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.6.2.4.1. Hospitals Pharmacies
13.6.2.4.2. Retail Pharmacies
13.6.2.4.3. Online Pharmacies
13.6.3. Spain
13.6.3.1. Spain Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Glaucoma Type
13.6.3.1.1. Open-Angle Glaucoma
13.6.3.1.2. Angle-Closure Glaucoma
13.6.3.1.3. Normal-Tension Glaucoma
13.6.3.1.4. Others
13.6.3.2. Spain Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Medication
13.6.3.2.1. Alpha Adrenergic Agonists
13.6.3.2.2. Beta Blockers
13.6.3.2.3. Carbonic Anhydrase Inhibitors
13.6.3.2.4. Miotics
13.6.3.2.5. Prostaglandin Analogs
13.6.3.2.6. Combination Medication
13.6.3.2.7. Others
13.6.3.3. Spain Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.6.3.3.1. Oral
13.6.3.3.2. Topical
13.6.3.4. Spain Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.6.3.4.1. Hospitals Pharmacies
13.6.3.4.2. Retail Pharmacies
13.6.3.4.3. Online Pharmacies
13.6.4. Germany
13.6.4.1. Germany Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Glaucoma Type
13.6.4.1.1. Open-Angle Glaucoma
13.6.4.1.2. Angle-Closure Glaucoma
13.6.4.1.3. Normal-Tension Glaucoma
13.6.4.1.4. Others
13.6.4.2. Germany Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Medication
13.6.4.2.1. Alpha Adrenergic Agonists
13.6.4.2.2. Beta Blockers
13.6.4.2.3. Carbonic Anhydrase Inhibitors
13.6.4.2.4. Miotics
13.6.4.2.5. Prostaglandin Analogs
13.6.4.2.6. Combination Medication
13.6.4.2.7. Others
13.6.4.3. Germany Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.6.4.3.1. Oral
13.6.4.3.2. Topical
13.6.4.4. Germany Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.6.4.4.1. Hospitals Pharmacies
13.6.4.4.2. Retail Pharmacies
13.6.4.4.3. Online Pharmacies
13.6.5. Italy
13.6.5.1. Italy Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Glaucoma Type
13.6.5.1.1. Open-Angle Glaucoma
13.6.5.1.2. Angle-Closure Glaucoma
13.6.5.1.3. Normal-Tension Glaucoma
13.6.5.1.4. Others
13.6.5.2. Italy Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Medication
13.6.5.2.1. Alpha Adrenergic Agonists
13.6.5.2.2. Beta Blockers
13.6.5.2.3. Carbonic Anhydrase Inhibitors
13.6.5.2.4. Miotics
13.6.5.2.5. Prostaglandin Analogs
13.6.5.2.6. Combination Medication
13.6.5.2.7. Others
13.6.5.3. Italy Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.6.5.3.1. Oral
13.6.5.3.2. Topical
13.6.5.4. Italy Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.6.5.4.1. Hospitals Pharmacies
13.6.5.4.2. Retail Pharmacies
13.6.5.4.3. Online Pharmacies
13.6.6. Nordic Countries
13.6.6.1. Nordic Countries Glaucoma Treatment Market Revenue (US$ Mn)
and Forecasts, By Glaucoma Type
13.6.6.1.1. Open-Angle Glaucoma
13.6.6.1.2. Angle-Closure Glaucoma
13.6.6.1.3. Normal-Tension Glaucoma
13.6.6.1.4. Others
13.6.6.2. Nordic Countries Glaucoma Treatment Market Revenue (US$ Mn)
and Forecasts, By Medication
13.6.6.2.1. Alpha Adrenergic Agonists
13.6.6.2.2. Beta Blockers
13.6.6.2.3. Carbonic Anhydrase Inhibitors
13.6.6.2.4. Miotics
13.6.6.2.5. Prostaglandin Analogs
13.6.6.2.6. Combination Medication
13.6.6.2.7. Others
13.6.6.3. Nordic Countries Glaucoma Treatment Market Revenue (US$ Mn)
and Forecasts, By Route of Administration
13.6.6.3.1. Oral
13.6.6.3.2. Topical
13.6.6.4. Nordic Countries Glaucoma Treatment Market Revenue (US$ Mn)
and Forecasts, By Distribution Channel
13.6.6.4.1. Hospitals Pharmacies
13.6.6.4.2. Retail Pharmacies
13.6.6.4.3. Online Pharmacies
13.6.6.5. Nordic Countries Glaucoma Treatment Market Revenue (US$ Mn)
and Forecasts, By Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux Union
13.6.7.1. Benelux Union Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Glaucoma Type
13.6.7.1.1. Open-Angle Glaucoma
13.6.7.1.2. Angle-Closure Glaucoma
13.6.7.1.3. Normal-Tension Glaucoma
13.6.7.1.4. Others
13.6.7.2. Benelux Union Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Medication
13.6.7.2.1. Alpha Adrenergic Agonists
13.6.7.2.2. Beta Blockers
13.6.7.2.3. Carbonic Anhydrase Inhibitors
13.6.7.2.4. Miotics
13.6.7.2.5. Prostaglandin Analogs
13.6.7.2.6. Combination Medication
13.6.7.2.7. Others
13.6.7.3. Benelux Union Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.6.7.3.1. Oral
13.6.7.3.2. Topical
13.6.7.4. Benelux Union Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.6.7.4.1. Hospitals Pharmacies
13.6.7.4.2. Retail Pharmacies
13.6.7.4.3. Online Pharmacies
13.6.7.5. Benelux Union Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of Europe
13.6.8.1. Rest of Europe Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Glaucoma Type
13.6.8.1.1. Open-Angle Glaucoma
13.6.8.1.2. Angle-Closure Glaucoma
13.6.8.1.3. Normal-Tension Glaucoma
13.6.8.1.4. Others
13.6.8.2. Rest of Europe Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Medication
13.6.8.2.1. Alpha Adrenergic Agonists
13.6.8.2.2. Beta Blockers
13.6.8.2.3. Carbonic Anhydrase Inhibitors
13.6.8.2.4. Miotics
13.6.8.2.5. Prostaglandin Analogs
13.6.8.2.6. Combination Medication
13.6.8.2.7. Others
13.6.8.3. Rest of Europe Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
13.6.8.3.1. Oral
13.6.8.3.2. Topical
13.6.8.4. Rest of Europe Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
13.6.8.4.1. Hospitals Pharmacies
13.6.8.4.2. Retail Pharmacies
13.6.8.4.3. Online Pharmacies
13.7. Key
Segment for Channeling Investments
13.7.1. By Country
13.7.2. By Glaucoma Type
13.7.3. By Medication
13.7.4. By Route of Administration
13.7.5. By Distribution Channel
14. Asia Pacific Glaucoma Treatment Market Analysis and
Forecasts, 2021 - 2029
14.1. Overview
14.1.1. Asia Pacific Glaucoma Treatment Market Revenue (US$ Mn)
14.2. Asia
Pacific Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By Glaucoma
Type
14.2.1. Open-Angle Glaucoma
14.2.2. Angle-Closure Glaucoma
14.2.3. Normal-Tension Glaucoma
14.2.4. Others
14.3. Asia
Pacific Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By Medication
14.3.1. Alpha Adrenergic Agonists
14.3.2. Beta Blockers
14.3.3. Carbonic Anhydrase Inhibitors
14.3.4. Miotics
14.3.5. Prostaglandin Analogs
14.3.6. Combination Medication
14.3.7. Others
14.4. Asia
Pacific Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.4.1. Oral
14.4.2. Topical
14.5. Asia
Pacific Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
14.5.1. Hospitals Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Asia
Pacific Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1. China Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Glaucoma Type
14.6.1.1.1. Open-Angle Glaucoma
14.6.1.1.2. Angle-Closure Glaucoma
14.6.1.1.3. Normal-Tension Glaucoma
14.6.1.1.4. Others
14.6.1.2. China Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Medication
14.6.1.2.1. Alpha Adrenergic Agonists
14.6.1.2.2. Beta Blockers
14.6.1.2.3. Carbonic Anhydrase Inhibitors
14.6.1.2.4. Miotics
14.6.1.2.5. Prostaglandin Analogs
14.6.1.2.6. Combination Medication
14.6.1.2.7. Others
14.6.1.3. China Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.6.1.3.1. Oral
14.6.1.3.2. Topical
14.6.1.4. China Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.6.1.4.1. Hospitals Pharmacies
14.6.1.4.2. Retail Pharmacies
14.6.1.4.3. Online Pharmacies
14.6.2. Japan
14.6.2.1. Japan Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Glaucoma Type
14.6.2.1.1. Open-Angle Glaucoma
14.6.2.1.2. Angle-Closure Glaucoma
14.6.2.1.3. Normal-Tension Glaucoma
14.6.2.1.4. Others
14.6.2.2. Japan Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Medication
14.6.2.2.1. Alpha Adrenergic Agonists
14.6.2.2.2. Beta Blockers
14.6.2.2.3. Carbonic Anhydrase Inhibitors
14.6.2.2.4. Miotics
14.6.2.2.5. Prostaglandin Analogs
14.6.2.2.6. Combination Medication
14.6.2.2.7. Others
14.6.2.3. Japan Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.6.2.3.1. Oral
14.6.2.3.2. Topical
14.6.2.4. Japan Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.6.2.4.1. Hospitals Pharmacies
14.6.2.4.2. Retail Pharmacies
14.6.2.4.3. Online Pharmacies
14.6.3. India
14.6.3.1. India Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Glaucoma Type
14.6.3.1.1. Open-Angle Glaucoma
14.6.3.1.2. Angle-Closure Glaucoma
14.6.3.1.3. Normal-Tension Glaucoma
14.6.3.1.4. Others
14.6.3.2. India Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Medication
14.6.3.2.1. Alpha Adrenergic Agonists
14.6.3.2.2. Beta Blockers
14.6.3.2.3. Carbonic Anhydrase Inhibitors
14.6.3.2.4. Miotics
14.6.3.2.5. Prostaglandin Analogs
14.6.3.2.6. Combination Medication
14.6.3.2.7. Others
14.6.3.3. India Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.6.3.3.1. Oral
14.6.3.3.2. Topical
14.6.3.4. India Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.6.3.4.1. Hospitals Pharmacies
14.6.3.4.2. Retail Pharmacies
14.6.3.4.3. Online Pharmacies
14.6.4. New Zealand
14.6.4.1. New Zealand Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Glaucoma Type
14.6.4.1.1. Open-Angle Glaucoma
14.6.4.1.2. Angle-Closure Glaucoma
14.6.4.1.3. Normal-Tension Glaucoma
14.6.4.1.4. Others
14.6.4.2. New Zealand Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Medication
14.6.4.2.1. Alpha Adrenergic Agonists
14.6.4.2.2. Beta Blockers
14.6.4.2.3. Carbonic Anhydrase Inhibitors
14.6.4.2.4. Miotics
14.6.4.2.5. Prostaglandin Analogs
14.6.4.2.6. Combination Medication
14.6.4.2.7. Others
14.6.4.3. New Zealand Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.6.4.3.1. Oral
14.6.4.3.2. Topical
14.6.4.4. New Zealand Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.6.4.4.1. Hospitals Pharmacies
14.6.4.4.2. Retail Pharmacies
14.6.4.4.3. Online Pharmacies
14.6.5. Australia
14.6.5.1. Australia Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Glaucoma Type
14.6.5.1.1. Open-Angle Glaucoma
14.6.5.1.2. Angle-Closure Glaucoma
14.6.5.1.3. Normal-Tension Glaucoma
14.6.5.1.4. Others
14.6.5.2. Australia Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Medication
14.6.5.2.1. Alpha Adrenergic Agonists
14.6.5.2.2. Beta Blockers
14.6.5.2.3. Carbonic Anhydrase Inhibitors
14.6.5.2.4. Miotics
14.6.5.2.5. Prostaglandin Analogs
14.6.5.2.6. Combination Medication
14.6.5.2.7. Others
14.6.5.3. Australia Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.6.5.3.1. Oral
14.6.5.3.2. Topical
14.6.5.4. Australia Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.6.5.4.1. Hospitals Pharmacies
14.6.5.4.2. Retail Pharmacies
14.6.5.4.3. Online Pharmacies
14.6.6. South Korea
14.6.6.1. South Korea Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Glaucoma Type
14.6.6.1.1. Open-Angle Glaucoma
14.6.6.1.2. Angle-Closure Glaucoma
14.6.6.1.3. Normal-Tension Glaucoma
14.6.6.1.4. Others
14.6.6.2. South Korea Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Medication
14.6.6.2.1. Alpha Adrenergic Agonists
14.6.6.2.2. Beta Blockers
14.6.6.2.3. Carbonic Anhydrase Inhibitors
14.6.6.2.4. Miotics
14.6.6.2.5. Prostaglandin Analogs
14.6.6.2.6. Combination Medication
14.6.6.2.7. Others
14.6.6.3. South Korea Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.6.6.3.1. Oral
14.6.6.3.2. Topical
14.6.6.4. South Korea Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.6.6.4.1. Hospitals Pharmacies
14.6.6.4.2. Retail Pharmacies
14.6.6.4.3. Online Pharmacies
14.6.7. Southeast Asia
14.6.7.1. Southeast Asia Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Glaucoma Type
14.6.7.1.1. Open-Angle Glaucoma
14.6.7.1.2. Angle-Closure Glaucoma
14.6.7.1.3. Normal-Tension Glaucoma
14.6.7.1.4. Others
14.6.7.2. Southeast Asia Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Medication
14.6.7.2.1. Alpha Adrenergic Agonists
14.6.7.2.2. Beta Blockers
14.6.7.2.3. Carbonic Anhydrase Inhibitors
14.6.7.2.4. Miotics
14.6.7.2.5. Prostaglandin Analogs
14.6.7.2.6. Combination Medication
14.6.7.2.7. Others
14.6.7.3. Southeast Asia Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
14.6.7.3.1. Oral
14.6.7.3.2. Topical
14.6.7.4. Southeast Asia Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
14.6.7.4.1. Hospitals Pharmacies
14.6.7.4.2. Retail Pharmacies
14.6.7.4.3. Online Pharmacies
14.6.7.5. Southeast Asia Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest of Southeast Asia
14.6.8. Rest of Asia Pacific
14.6.8.1. Rest of Asia Pacific Glaucoma Treatment Market Revenue (US$
Mn) and Forecasts, By Glaucoma Type
14.6.8.1.1. Open-Angle Glaucoma
14.6.8.1.2. Angle-Closure Glaucoma
14.6.8.1.3. Normal-Tension Glaucoma
14.6.8.1.4. Others
14.6.8.2. Rest of Asia Pacific Glaucoma Treatment Market Revenue (US$
Mn) and Forecasts, By Medication
14.6.8.2.1. Alpha Adrenergic Agonists
14.6.8.2.2. Beta Blockers
14.6.8.2.3. Carbonic Anhydrase Inhibitors
14.6.8.2.4. Miotics
14.6.8.2.5. Prostaglandin Analogs
14.6.8.2.6. Combination Medication
14.6.8.2.7. Others
14.6.8.3. Rest of Asia Pacific Glaucoma Treatment Market Revenue (US$
Mn) and Forecasts, By Route of Administration
14.6.8.3.1. Oral
14.6.8.3.2. Topical
14.6.8.4. Rest of Asia Pacific Glaucoma Treatment Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
14.6.8.4.1. Hospitals Pharmacies
14.6.8.4.2. Retail Pharmacies
14.6.8.4.3. Online Pharmacies
14.7. Key
Segment for Channeling Investments
14.7.1. By Country
14.7.2. By Glaucoma Type
14.7.3. By Medication
14.7.4. By Route of Administration
14.7.5. By Distribution Channel
15. Middle East and Africa Glaucoma Treatment Market Analysis and
Forecasts, 2021 - 2029
15.1. Overview
15.1.1. Middle East and Africa Glaucoma Treatment Market Revenue (US$
Mn)
15.2. Middle
East and Africa Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By
Glaucoma Type
15.2.1. Open-Angle Glaucoma
15.2.2. Angle-Closure Glaucoma
15.2.3. Normal-Tension Glaucoma
15.2.4. Others
15.3. Middle
East and Africa Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By Medication
15.3.1. Alpha Adrenergic Agonists
15.3.2. Beta Blockers
15.3.3. Carbonic Anhydrase Inhibitors
15.3.4. Miotics
15.3.5. Prostaglandin Analogs
15.3.6. Combination Medication
15.3.7. Others
15.4. Middle
East and Africa Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
15.4.1. Oral
15.4.2. Topical
15.5. Middle
East and Africa Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
15.5.1. Hospitals Pharmacies
15.5.2. Retail Pharmacies
15.5.3. Online Pharmacies
15.6. Middle
East and Africa Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By
Country
15.6.1. Saudi Arabia
15.6.1.1. Saudi Arabia Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Glaucoma Type
15.6.1.1.1. Open-Angle Glaucoma
15.6.1.1.2. Angle-Closure Glaucoma
15.6.1.1.3. Normal-Tension Glaucoma
15.6.1.1.4. Others
15.6.1.2. Saudi Arabia Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Medication
15.6.1.2.1. Alpha Adrenergic Agonists
15.6.1.2.2. Beta Blockers
15.6.1.2.3. Carbonic Anhydrase Inhibitors
15.6.1.2.4. Miotics
15.6.1.2.5. Prostaglandin Analogs
15.6.1.2.6. Combination Medication
15.6.1.2.7. Others
15.6.1.3. Saudi Arabia Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
15.6.1.3.1. Oral
15.6.1.3.2. Topical
15.6.1.4. Saudi Arabia Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
15.6.1.4.1. Hospitals Pharmacies
15.6.1.4.2. Retail Pharmacies
15.6.1.4.3. Online Pharmacies
15.6.2. UAE
15.6.2.1. UAE Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts,
By Glaucoma Type
15.6.2.1.1. Open-Angle Glaucoma
15.6.2.1.2. Angle-Closure Glaucoma
15.6.2.1.3. Normal-Tension Glaucoma
15.6.2.1.4. Others
15.6.2.2. UAE Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts,
By Medication
15.6.2.2.1. Alpha Adrenergic Agonists
15.6.2.2.2. Beta Blockers
15.6.2.2.3. Carbonic Anhydrase Inhibitors
15.6.2.2.4. Miotics
15.6.2.2.5. Prostaglandin Analogs
15.6.2.2.6. Combination Medication
15.6.2.2.7. Others
15.6.2.3. UAE Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
15.6.2.3.1. Oral
15.6.2.3.2. Topical
15.6.2.4. UAE Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts,
By Distribution Channel
15.6.2.4.1. Hospitals Pharmacies
15.6.2.4.2. Retail Pharmacies
15.6.2.4.3. Online Pharmacies
15.6.3. Egypt
15.6.3.1. Egypt Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Glaucoma Type
15.6.3.1.1. Open-Angle Glaucoma
15.6.3.1.2. Angle-Closure Glaucoma
15.6.3.1.3. Normal-Tension Glaucoma
15.6.3.1.4. Others
15.6.3.2. Egypt Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Medication
15.6.3.2.1. Alpha Adrenergic Agonists
15.6.3.2.2. Beta Blockers
15.6.3.2.3. Carbonic Anhydrase Inhibitors
15.6.3.2.4. Miotics
15.6.3.2.5. Prostaglandin Analogs
15.6.3.2.6. Combination Medication
15.6.3.2.7. Others
15.6.3.3. Egypt Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
15.6.3.3.1. Oral
15.6.3.3.2. Topical
15.6.3.4. Egypt Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
15.6.3.4.1. Hospitals Pharmacies
15.6.3.4.2. Retail Pharmacies
15.6.3.4.3. Online Pharmacies
15.6.4. Kuwait
15.6.4.1. Kuwait Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Glaucoma Type
15.6.4.1.1. Open-Angle Glaucoma
15.6.4.1.2. Angle-Closure Glaucoma
15.6.4.1.3. Normal-Tension Glaucoma
15.6.4.1.4. Others
15.6.4.2. Kuwait Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Medication
15.6.4.2.1. Alpha Adrenergic Agonists
15.6.4.2.2. Beta Blockers
15.6.4.2.3. Carbonic Anhydrase Inhibitors
15.6.4.2.4. Miotics
15.6.4.2.5. Prostaglandin Analogs
15.6.4.2.6. Combination Medication
15.6.4.2.7. Others
15.6.4.3. Kuwait Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
15.6.4.3.1. Oral
15.6.4.3.2. Topical
15.6.4.4. Kuwait Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
15.6.4.4.1. Hospitals Pharmacies
15.6.4.4.2. Retail Pharmacies
15.6.4.4.3. Online Pharmacies
15.6.5. South Africa
15.6.5.1. South Africa Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Glaucoma Type
15.6.5.1.1. Open-Angle Glaucoma
15.6.5.1.2. Angle-Closure Glaucoma
15.6.5.1.3. Normal-Tension Glaucoma
15.6.5.1.4. Others
15.6.5.2. South Africa Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Medication
15.6.5.2.1. Alpha Adrenergic Agonists
15.6.5.2.2. Beta Blockers
15.6.5.2.3. Carbonic Anhydrase Inhibitors
15.6.5.2.4. Miotics
15.6.5.2.5. Prostaglandin Analogs
15.6.5.2.6. Combination Medication
15.6.5.2.7. Others
15.6.5.3. South Africa Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
15.6.5.3.1. Oral
15.6.5.3.2. Topical
15.6.5.4. South Africa Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
15.6.5.4.1. Hospitals Pharmacies
15.6.5.4.2. Retail Pharmacies
15.6.5.4.3. Online Pharmacies
15.6.6. Rest of Middle East & Africa
15.6.6.1. Rest of Middle East & Africa Glaucoma Treatment Market
Revenue (US$ Mn) and Forecasts, By Glaucoma Type
15.6.6.1.1. Open-Angle Glaucoma
15.6.6.1.2. Angle-Closure Glaucoma
15.6.6.1.3. Normal-Tension Glaucoma
15.6.6.1.4. Others
15.6.6.2. Rest of Middle East & Africa Glaucoma Treatment Market
Revenue (US$ Mn) and Forecasts, By Medication
15.6.6.2.1. Alpha Adrenergic Agonists
15.6.6.2.2. Beta Blockers
15.6.6.2.3. Carbonic Anhydrase Inhibitors
15.6.6.2.4. Miotics
15.6.6.2.5. Prostaglandin Analogs
15.6.6.2.6. Combination Medication
15.6.6.2.7. Others
15.6.6.3. Rest of Middle East & Africa Glaucoma Treatment Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
15.6.6.3.1. Oral
15.6.6.3.2. Topical
15.6.6.4. Rest of Middle East & Africa Glaucoma Treatment Market
Revenue (US$ Mn) and Forecasts, By Distribution Channel
15.6.6.4.1. Hospitals Pharmacies
15.6.6.4.2. Retail Pharmacies
15.6.6.4.3. Online Pharmacies
15.7. Key
Segment for Channeling Investments
15.7.1. By Country
15.7.2. By Glaucoma Type
15.7.3. By Medication
15.7.4. By Route of Administration
15.7.5. By Distribution Channel
16. Latin America Glaucoma Treatment Market Analysis and
Forecasts, 2021 - 2029
16.1. Overview
16.1.1. Latin America Glaucoma Treatment Market Revenue (US$ Mn)
16.2. Latin
America Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By Glaucoma
Type
16.2.1. Open-Angle Glaucoma
16.2.2. Angle-Closure Glaucoma
16.2.3. Normal-Tension Glaucoma
16.2.4. Others
16.3. Latin
America Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By Medication
16.3.1. Alpha Adrenergic Agonists
16.3.2. Beta Blockers
16.3.3. Carbonic Anhydrase Inhibitors
16.3.4. Miotics
16.3.5. Prostaglandin Analogs
16.3.6. Combination Medication
16.3.7. Others
16.4. Latin
America Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
16.4.1. Oral
16.4.2. Topical
16.5. Latin
America Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By
Distribution Channel
16.5.1. Hospitals Pharmacies
16.5.2. Retail Pharmacies
16.5.3. Online Pharmacies
16.6. Latin
America Glaucoma Treatment Market Revenue (US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1. Brazil Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Glaucoma Type
16.6.1.1.1. Open-Angle Glaucoma
16.6.1.1.2. Angle-Closure Glaucoma
16.6.1.1.3. Normal-Tension Glaucoma
16.6.1.1.4. Others
16.6.1.2. Brazil Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Medication
16.6.1.2.1. Alpha Adrenergic Agonists
16.6.1.2.2. Beta Blockers
16.6.1.2.3. Carbonic Anhydrase Inhibitors
16.6.1.2.4. Miotics
16.6.1.2.5. Prostaglandin Analogs
16.6.1.2.6. Combination Medication
16.6.1.2.7. Others
16.6.1.3. Brazil Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
16.6.1.3.1. Oral
16.6.1.3.2. Topical
16.6.1.4. Brazil Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
16.6.1.4.1. Hospitals Pharmacies
16.6.1.4.2. Retail Pharmacies
16.6.1.4.3. Online Pharmacies
16.6.2. Argentina
16.6.2.1. Argentina Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Glaucoma Type
16.6.2.1.1. Open-Angle Glaucoma
16.6.2.1.2. Angle-Closure Glaucoma
16.6.2.1.3. Normal-Tension Glaucoma
16.6.2.1.4. Others
16.6.2.2. Argentina Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Medication
16.6.2.2.1. Alpha Adrenergic Agonists
16.6.2.2.2. Beta Blockers
16.6.2.2.3. Carbonic Anhydrase Inhibitors
16.6.2.2.4. Miotics
16.6.2.2.5. Prostaglandin Analogs
16.6.2.2.6. Combination Medication
16.6.2.2.7. Others
16.6.2.3. Argentina Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
16.6.2.3.1. Oral
16.6.2.3.2. Topical
16.6.2.4. Argentina Glaucoma Treatment Market Revenue (US$ Mn) and
Forecasts, By Distribution Channel
16.6.2.4.1. Hospitals Pharmacies
16.6.2.4.2. Retail Pharmacies
16.6.2.4.3. Online Pharmacies
16.6.3. Rest of Latin America
16.6.3.1. Rest of Latin America Glaucoma Treatment Market Revenue (US$
Mn) and Forecasts, By Glaucoma Type
16.6.3.1.1. Open-Angle Glaucoma
16.6.3.1.2. Angle-Closure Glaucoma
16.6.3.1.3. Normal-Tension Glaucoma
16.6.3.1.4. Others
16.6.3.2. Rest of Latin America Glaucoma Treatment Market Revenue (US$
Mn) and Forecasts, By Medication
16.6.3.2.1. Alpha Adrenergic Agonists
16.6.3.2.2. Beta Blockers
16.6.3.2.3. Carbonic Anhydrase Inhibitors
16.6.3.2.4. Miotics
16.6.3.2.5. Prostaglandin Analogs
16.6.3.2.6. Combination Medication
16.6.3.2.7. Others
16.6.3.3. Rest of Latin America Glaucoma Treatment Market Revenue (US$
Mn) and Forecasts, By Route of Administration
16.6.3.3.1. Oral
16.6.3.3.2. Topical
16.6.3.4. Rest of Latin America Glaucoma Treatment Market Revenue (US$
Mn) and Forecasts, By Distribution Channel
16.6.3.4.1. Hospitals Pharmacies
16.6.3.4.2. Retail Pharmacies
16.6.3.4.3. Online Pharmacies
16.7. Key
Segment for Channeling Investments
16.7.1. By Country
16.7.2. By Glaucoma Type
16.7.3. By Medication
16.7.4. By Route of Administration
16.7.5. By Distribution Channel
17. Competitive Benchmarking
17.1. Market
Share Analysis, 2020
17.2. Global
Presence and Growth Strategies
17.2.1. Mergers and Acquisitions
17.2.2. Product Launches
17.2.3. Investments Trends
17.2.4. R&D Initiatives
18. Player Profiles
18.1. Aerie
Pharmaceuticals, Inc.
18.1.1. Company Details
18.1.2. Company Overview
18.1.3. Product Offerings
18.1.4. Key Developments
18.1.5. Financial Analysis
18.1.6. SWOT Analysis
18.1.7. Business Strategies
18.2. ALLERGAN
18.2.1. Company Details
18.2.2. Company Overview
18.2.3. Product Offerings
18.2.4. Key Developments
18.2.5. Financial Analysis
18.2.6. SWOT Analysis
18.2.7. Business Strategies
18.3. Bausch & Lomb Incorporated
18.3.1. Company Details
18.3.2. Company Overview
18.3.3. Product Offerings
18.3.4. Key Developments
18.3.5. Financial Analysis
18.3.6. SWOT Analysis
18.3.7. Business Strategies
18.4. EyeD Pharma s.a.
18.4.1. Company Details
18.4.2. Company Overview
18.4.3. Product Offerings
18.4.4. Key Developments
18.4.5. Financial Analysis
18.4.6. SWOT Analysis
18.4.7. Business Strategies
18.5. Merck & Co., Inc.
18.5.1. Company Details
18.5.2. Company Overview
18.5.3. Product Offerings
18.5.4. Key Developments
18.5.5. Financial Analysis
18.5.6. SWOT Analysis
18.5.7. Business Strategies
18.6. Pfizer
18.6.1. Company Details
18.6.2. Company Overview
18.6.3. Product Offerings
18.6.4. Key Developments
18.6.5. Financial Analysis
18.6.6. SWOT Analysis
18.6.7. Business Strategies
18.7. Santen Pharmaceutical Co., Ltd.
18.7.1. Company Details
18.7.2. Company Overview
18.7.3. Product Offerings
18.7.4. Key Developments
18.7.5. Financial Analysis
18.7.6. SWOT Analysis
18.7.7. Business Strategies
18.8. Senju Pharmaceutical Co.,Ltd.
18.8.1. Company Details
18.8.2. Company Overview
18.8.3. Product Offerings
18.8.4. Key Developments
18.8.5. Financial Analysis
18.8.6. SWOT Analysis
18.8.7. Business Strategies
18.9. Sunways India Pvt Ltd.
18.9.1. Company Details
18.9.2. Company Overview
18.9.3. Product Offerings
18.9.4. Key Developments
18.9.5. Financial Analysis
18.9.6. SWOT Analysis
18.9.7. Business Strategies
18.10. Other
Market Participants
19. Key Findings
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.